News & Updates
Filter by Specialty:
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
20 Apr 2023
Certain reproductive factors tied to premature menopause in Asians
Women with histories of infertility, recurrent miscarriages, and stillbirths are more likely to experience premature or early menopause, with stronger associations observed for Asian women, as reported in a study.
Certain reproductive factors tied to premature menopause in Asians
20 Apr 2023
COVID-19 medicine use in pregnancy increases with disease severity
Use of medicines for COVID-19 during pregnancy is higher in patients with more severe disease, according to a study. In addition, a trend towards increased corticosteroids use has been observed and appears to be consistent with changing guidelines.
COVID-19 medicine use in pregnancy increases with disease severity
19 Apr 2023
Excess CVD risk found in women with endometriosis
Endometriosis appears to be associated with a significantly elevated risk of cardiovascular disease (CVD), specifically ischaemic heart disease and cerebrovascular disease, as suggested in a study.
Excess CVD risk found in women with endometriosis
17 Apr 2023
Add-on immunotherapy improves PFS in 1L advanced or recurrent endometrial cancer
Adding dostarlimab or pembrolizumab to standard first-line (1L) chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, two phase III trials have shown.